Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, ...

Compound heterozygotes and complex cases had a higher frequency of abdominal pain, fever, arthralgia, arthritis, myalgia, and chest pain than subjects who were homozygous for E148Q, but none of these ...

Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for ...

Two ARIA-related deaths were attributed to donanemab in that study. ARIA occurred more frequently in APOE4 homozygotes than ...

Genetic polymorphisms have been described in the case of several CYP isoenzymes. The best explored example of this phenomenon is the CYP2C19 polymorphism. In this table the most frequent alleles ...

Dietary protein absorption in neonatal mammals and fishes relies on the function of a specialized and conserved population of highly absorptive lysosome rich enterocytes (LREs). The gut microbiome has ...

It allows one to discriminate the carriers of the trait, who presumably are heterozygotes, from carriers of the various cystinuric genotypes. The trait is expressed consistently with regard to ...

UK MHRA grants marketing approval to Lilly's Kisunla to treat mild cognitive impairment and mild dementia due to Alzheimer's disease: Indianapolis Thursday, October 24, 2024, 09:0 ...

It comes on the same day as donanemab was awarded a licence by the Medicines and Healthcare products Regulatory Agency (MHRA) ...